OssDsign AB (publ) Stock Price

OM:OSSD Community·SEK 400.5m Market Cap

3 Narratives written by author
0 Comments on narratives written by author
8 Fair Values set on narratives written by author

Author Program NEW Create Narrative

OSSD Share Price Performance

SEK 3.62

-11.58 (-76.18%)

SEK 6.40

Fair Value

SEK 3.62

-11.58 (-76.18%)

43.4% undervalued

SEK 6.40

Fair Value

SEK 3.62

SEK 6.40

SEK 9.00

SEK 5.10

Thu, 2 Jul 26

Fair ValueSEK 6.40

Share Pricen/a

OSSD Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value SEK 6.4 43.4% undervalued

Pure Play Orthobiologics Will Expand US Healthcare Access

AnalystHighTarget's

Fair Value

Fair Value SEK 9 59.8% undervalued

U.S. Spine Market Penetration And New Orthopedic Indications Will Drive Exceptional Future Upside

AnalystLowTarget's

Fair Value

Fair Value SEK 5.1 29.0% undervalued

Rising US Healthcare Cost Controls Will Squeeze Orthobiologics Margins

OssDsign

43.4% undervalued

Pure Play Orthobiologics Will Expand US Healthcare Access

AnalystConsensusTarget

Updated 2 Jul

Read Narrative

OssDsign

59.8% undervalued

U.S. Spine Market Penetration And New Orthopedic Indications Will Drive Exceptional Future Upside

AnalystHighTarget

Updated 17 Jul

Read Narrative

OssDsign

29.0% undervalued

Rising US Healthcare Cost Controls Will Squeeze Orthobiologics Margins

AnalystLowTarget

Updated 18 Jun

Read Narrative

Trending Discussion

No trending discussion available.

Snowflake Analysis

Flawless balance sheet and fair value.

2 Risks

2 Rewards

View Full Analysis

OssDsign AB (publ) Key Details

Last Reported Earnings

Jun 30, 2026

Next Reporting Earnings

Nov 03, 2026

: -0.46
: 94.10%
: -31.11%
: 0%

View Full Analysis

About OSSD

Founded: 2011
Employees: 41
CEO: Mark Waugh
WebsiteView website: www.ossdsign.com

OssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in the United States. The company offers OssDsign Catalyst, a nanosynthetic bone graft engages in dual bone formation pathways through fusion mass. OssDsign AB (publ) was founded in 2011 and is headquartered in Uppsala, Sweden.

Recent OSSD News & Updates

Narrative Update • Jul 17

nan

Analysts have reduced their price target for OssDsign from SEK 17.50 to SEK 9.00, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for OssDsign No recent OssDsign specific news items were identified in the provided sources.

Recent updates

No updates

OssDsign AB (publ) Competitors

OssDsign AB (publ) Stock Price

OSSD Share Price Performance

OSSD Community Narratives

Pure Play Orthobiologics Will Expand US Healthcare Access

U.S. Spine Market Penetration And New Orthopedic Indications Will Drive Exceptional Future Upside

Rising US Healthcare Cost Controls Will Squeeze Orthobiologics Margins

Pure Play Orthobiologics Will Expand US Healthcare Access

U.S. Spine Market Penetration And New Orthopedic Indications Will Drive Exceptional Future Upside

Rising US Healthcare Cost Controls Will Squeeze Orthobiologics Margins

Trending Discussion

Recently Updated Narratives

nan

OSSD: Higher Margin Outlook And Lower P/E Will Support Future Re Rating

OSSD: Refined Forecast Assumptions And Q1 2026 Guidance Support Upside Potential

Snowflake Analysis

OssDsign AB (publ) Key Details

About OSSD

Recent OSSD News & Updates

Consensus EPS estimates upgraded to kr0.42 loss, revenue downgraded

Second quarter 2026 earnings: Revenues miss analyst expectations

nan

Recent updates

OssDsign AB (publ) Competitors

MedCap

Xvivo Perfusion

Arjo

RaySearch Laboratories